Praxis Precision Medicines/$PRAX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Praxis Precision Medicines
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
- Ticker
- $PRAX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 168
- Headquarters
- Boston, United States
- Website
- praxismedicines.com
PRAX Metrics
BasicAdvanced
$8B
-
-$12.86
2.78
-
Price and volume
Market cap
$8B
Beta
2.78
52-week high
$392.70
52-week low
$154.45
Average daily volume
533K
Financial strength
Current ratio
28.917
Quick ratio
28.639
Long term debt to equity
0.001
Total debt to equity
0.001
Profitability
EBITDA (TTM)
-378.048
Management effectiveness
Return on assets (TTM)
-25.65%
Return on equity (TTM)
-38.86%
Valuation
Price to book
5.95
Price to tangible book (TTM)
5.95
Price to free cash flow (TTM)
-24.633
Free cash flow yield (TTM)
-4.06%
Free cash flow per share (TTM)
-11.608
Growth
Earnings per share change (TTM)
4.28%
3-year earnings per share growth (CAGR)
-33.39%
What the Analysts think about PRAX
Analyst ratings (Buy, Hold, Sell) for Praxis Precision Medicines stock.
Analyst projections of the future price of Praxis Precision Medicines stock.
Bulls say / Bears say
Ulixacaltamide could give Praxis a first-mover opportunity in essential tremor: it is the first investigational treatment to report positive Phase 3 results for a condition affecting about seven million people in the US. The FDA’s mid-cycle review found no major safety or efficacy concerns, and no advisory committee meeting is planned. (Praxis Precision Medicines)
Relutrigine offers a second near-term approval catalyst in rare genetic epilepsy and, if approved, could be the first treatment for SCN2A and SCN8A developmental and epileptic encephalopathies. Its FDA review found no major safety or efficacy concerns, with a decision due by 27 December 2026. (Praxis Precision Medicines)
Elsunersen adds longer-term pipeline potential: positive results from its early study led to the FDA granting Breakthrough Therapy Designation. Its registrational EMBRAVE3 study is enrolling, with results expected in 2027. (Praxis Precision Medicines)
Vormatrigine failed to meet the primary endpoint in the POWER1 focal-seizure study, and Praxis paused enrolment in another trial while it reassessed the programme. That leaves the drug’s development path and commercial potential less certain. (Reuters)
The FDA classified additional sensitivity analyses for relutrigine as a major amendment, pushing its decision date back three months to 27 December 2026. The delay creates further uncertainty for a key near-term approval catalyst. (Praxis Precision Medicines)
Praxis is still making substantial losses as it builds towards commercial launches: its second-quarter net loss widened to $83.7 million from $71.1 million a year earlier, while general and administrative expenses more than doubled. The company has sizeable cash reserves, but it must turn that rising spend into approved products and sales. (Praxis Precision Medicines)
Data summarised monthly by Lightyear AI. Last updated on 19 Oct 2026.
PRAX Financial Performance
Revenues and expenses
PRAX Earnings Performance
Company profitability
Upcoming events
No upcoming events
PRAX News
AllArticlesVideos
Funds containing PRAX
AllUSDEURGBP
Fund name | Fund size | $PRAX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.52% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.52% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.24% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.24% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.10% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.